Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivesto ABOASMY 26 Equity-to-Asset is 0.94 as of Mar. 2026, which is 15% above its 10-year median of 0.82. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Vivesto AB ranks better than 97.32% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vivesto AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $17.88 Mil. Vivesto AB's Total Assets for the quarter that ended in Mar. 2026 was $19.09 Mil.
The historical rank and industry rank for Vivesto AB's Equity-to-Asset or its related term are showing as below:
OASMY'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.56 Med: 0.82 Max: 0.95
Current: 0.94
During the past 13 years, the highest Equity to Asset Ratio of Vivesto AB was 0.95. The lowest was 0.56. And the median was 0.82.
OASMY's Equity-to-Asset is ranked better than 97.32% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs OASMY: 0.94
Vivesto AB (OTCPK:OASMY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vivesto AB Equity-to-Asset Related Terms
Vivesto AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Vivesto AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vivesto AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vivesto AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivesto AB (OASMY) has a Equity-to-Asset of 0.94 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vivesto AB and its competitors. This is 15% above median its historical median of 0.82. Over the past decade, Vivesto AB's Equity-to-Asset has ranged from 0.56 to 0.95. According to the industry distribution chart, Vivesto AB ranks #27 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Vivesto AB's Equity-to-Asset too high?
Vivesto AB's current Equity-to-Asset of 0.94 is 15% above median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 0.95. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Vivesto AB's value of 0.94 is 54.1% above this industry median. Based on the distribution chart, Vivesto AB ranks #27 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #27 out of 1006 companies for Equity-to-Asset. This places Vivesto AB in the top 3% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Vivesto AB's value of 0.94 is 54.1% above this benchmark. Historically, Vivesto AB's own Equity-to-Asset has ranged from 0.56 to 0.95 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.61, Vivesto AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivesto AB's current Equity-to-Asset of 0.94 is 54.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current Equity-to-Asset is 0.94, which is 15% above median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current Equity-to-Asset of 0.94. The current Equity-to-Asset is 0.94, which is 15% above median its 10-year median of 0.82 and 54.1% above the Drug Manufacturers industry median of 0.61. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Vivesto AB (OASMY), the current Equity-to-Asset is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OASMY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OASMY has been successfully added to your 
